Rasagiline

Structural formula
General
Non-proprietary name	Rasagiline
other names	( R ) - N -2-propynyl-1-indanamine; ( R ) - N -prop-2-ynyl-2,3-dihydro-1 H -inden-1-amine;
Molecular formula	C 12 H 13 N (rasagiline) ; C 12 H 13 N CH 4 O 3 S (rasagiline methyl sulfonate) ;
External identifiers / databases
PubChem	3052776
DrugBank	DB01367
Wikidata	Q420685
Drug information
ATC code	N04 BD02
Drug class	Monoamine oxidase inhibitors
Mechanism of action	irreversible inhibition of MAO-B
properties
Molar mass	171.24 g mol −1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Rasagiline is a medicine used to treat Parkinson's disease . In the countries of the European Union it has been approved as methanesulfonate salt since July 2005 under the trade name Azilect ^® . Rasagiline belongs to the group of selective irreversible monoamine oxidase inhibitors (MAOIs) and is a second generation MAO-B inhibitor . It inhibits MAO-B five to ten times more than the selegiline available from this group .

Despite the short half-life of the rasagiline of 0.6–2 hours , only one administration per day is required, since the MAO-B is irreversibly blocked. The clinical duration of action is therefore determined by the rate of biosynthesis of the enzyme in the body.

Rasagiline is approved for the early monotherapy of idiopathic Parkinson's syndrome, with symptomatic efficacy and a delay in the start of treatment with dopaminergic therapy has been partially proven by controlled studies . Rasagiline is also approved for the combination treatment of patients with motor fluctuations.

Trade names

Rasagiline is commercially available in Germany, Austria, Switzerland and the EU under the name Azilect from Teva and Lundbeck .

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ M. Naoi, W. Maruyama, K. Inaba-Hasegawa: Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival. In: Current Topics in Medicinal Chemistry . Volume 12, Number 20, 2012, pp. 2177-2188, PMID 23231395 .
↑ J. Leegwater-Kim, E. Bortan: The role of rasagiline in the treatment of Parkinson's disease. In: Clinical interventions in aging. Volume 5, 2010, pp. 149-156, PMID 20517484 . PMC 2877525 (free full text).
^ S. Giordano, V. Darley-Usmar, J. Zhang: Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. In: Redox biology. Volume 2, 2014, pp. 82-90, doi : 10.1016 / j.redox.2013.12.013 . PMID 24494187 . PMC 3909266 (free full text).

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[2] M. Naoi, W. Maruyama, K. Inaba-Hasegawa: Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival. In: Current Topics in Medicinal Chemistry . Volume 12, Number 20, 2012, pp. 2177-2188, PMID 23231395 .

[3] J. Leegwater-Kim, E. Bortan: The role of rasagiline in the treatment of Parkinson's disease. In: Clinical interventions in aging. Volume 5, 2010, pp. 149-156, PMID 20517484 . PMC 2877525 (free full text).

[4] S. Giordano, V. Darley-Usmar, J. Zhang: Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. In: Redox biology. Volume 2, 2014, pp. 82-90, doi : 10.1016 / j.redox.2013.12.013 . PMID 24494187 . PMC 3909266 (free full text).